Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.57 |
| ▸ | ESR1 | P03372 | 7/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | ABAT | P80404 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20763851 | 1.00 | TAAR1 (0.57) | TAAR1SLC6A2ESR1OPRK1SLC7A5 | |
| SCHEMBL23986747 | 0.82 | SLC6A4 (0.42) | TAAR1SLC6A2SLC6A4 | |
| SCHEMBL23986762 | 0.82 | SLC6A4 (0.43) | TAAR1SLC6A2SLC6A4 | |
| SCHEMBL25833300 | 0.81 | TAAR1 (0.49) | TAAR1SLC6A2ESR1OPRK1SLC7A5 | |
| SCHEMBL24140474 | 0.81 | SLC7A5 (0.53) | TAAR1SLC6A2ESR1OPRK1SLC7A5 | |
| SCHEMBL27124358 | 0.81 | SLC7A5 (0.53) | TAAR1SLC6A2ESR1OPRK1SLC7A5 | |
| SCHEMBL2627109 | 0.81 | TRPA1 (0.43) | TAAR1SLC6A4 | |
| SCHEMBL20992605 | 0.80 | EPHX1 (0.64) | TAAR1SLC6A2SLC7A5SLC6A4 | |
| SCHEMBL15250377 | 0.80 | EPHX1 (0.64) | TAAR1SLC6A2SLC7A5SLC6A4 | |
| SCHEMBL13227777 | 0.80 | EPHX1 (0.64) | TAAR1SLC6A2SLC7A5SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190055279-A1 | NOVEL POLYPEPTIDES WITH IMPROVED PROTEOLYTIC STABILITY, AND METHODS OF PREPARING AND USING SAME | TUFTS UNIVERSITY (US) | 2019-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190055279-A1 | NOVEL POLYPEPTIDES WITH IMPROVED PROTEOLYTIC STABILITY, AND METHODS OF PREPARING AND USING SAME | PTMS, ANPEP, DNPEP | TAAR1 4403/4885SLC6A2 4823/4885ESR1 4393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.